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THE PRACTICE OF EMERGENCY MEDICINE/CONCEPTS

Consensus Recommendations on the Treatment of
Opioid Use Disorder in the Emergency
Department
Kathryn Hawk, MD, MHS*; Jason Hoppe, DO; Eric Ketcham, MD; Alexis LaPietra, DO; Aimee Moulin, MD; Lewis Nelson, MD;
Evan Schwarz, MD; Sam Shahid, MBBS, MPH; Donald Stader, MD; Michael P. Wilson, MD; Gail D’Onofrio, MD, MS
*Corresponding Author. E-mail: kathryn.hawk@yale.edu.

The treatment of opioid use disorder with buprenorphine and methadone reduces morbidity and mortality in patients with opioid use
disorder. The initiation of buprenorphine in the emergency department (ED) has been associated with increased rates of outpatient
treatment linkage and decreased drug use when compared to patients randomized to receive standard ED referral. As such, the ED
has been increasingly recognized as a venue for the identiﬁcation and initiation of treatment for opioid use disorder, but no formal
American College of Emergency Physicians (ACEP) recommendations on the topic have previously been published. The ACEP
convened a group of emergency physicians with expertise in clinical research, addiction, toxicology, and administration to review
literature and develop consensus recommendations on the treatment of opioid use disorder in the ED. Based on literature review,
clinical experience, and expert consensus, the group recommends that emergency physicians offer to initiate opioid use disorder
treatment with buprenorphine in appropriate patients and provide direct linkage to ongoing treatment for patients with untreated
opioid use disorder. These consensus recommendations include strategies for opioid use disorder treatment initiation and ED
program implementation. They were approved by the ACEP board of directors in January 2021. [Ann Emerg Med. 2021;78:434-442.]
0196-0644/$-see front matter
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creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.annemergmed.2021.04.023

INTRODUCTION
In 2019, the National Safety Council announced that
for the ﬁrst time in history, a person in the United States
was more likely to die of an unintentional opioid overdose
than in a motor vehicle collision.1 After a brief decrease in
opioid-associated mortality from 2017 to 2018 of 1.7%
(47,600 to 46,802), the US Centers for Disease Control
and Prevention (CDC) reported 50,042 deaths in 2019, an
increase of 9.4%, with even greater increases in overdose
deaths projected due to the coronavirus disease 2019
(COVID-19) pandemic.2 Provisional reporting by the
CDC reveals new increases in rates of drug overdose in all
US states, with an overall increase in drug overdose deaths
of 26.8% and 19 states showing increases of more than
30% between August 2019 and August 2020.2 Increased
availability of highly potent illicit fentanyl and fentanyl
analogues and the social isolation and treatment
interruption associated with the COVID-19 pandemic
represent drivers of the worsening opioid crisis, augmenting
existing barriers and treatment gaps in the opioid cascade of
care, a quality measurement framework that includes
treatment engagement, medication initiation, retention,
434 Annals of Emergency Medicine

and remission.3-6 The treatment of opioid use disorder with
buprenorphine or methadone has been associated with
improved quality of life, reduced drug use, diminished
HIV/Hepatitis C transmission, reduced opioid overdose,
and decreased all-cause mortality.7-12 With only 18% of
individuals with opioid use disorder receiving medication
for opioid use disorder treatment within the past year,13
opioid overdose remains the leading cause of unintentional
death for adults under the age of 50 in the United States,
claiming an average of approximately 130 lives every day.14
The Opioid Crisis and Emergency Departments
The ﬁrst 2 decades of this millennium were
characterized by dramatic increases in rates of opioid
prescription, opioid overdose, and opioid-related utilization
of inpatient and emergency department (ED) care.15-17 As
the opioid crisis has worsened, ED visits for opioid-related
adverse drug events, complications of injection drug use,
and opioid withdrawal have become increasingly common,
resulting in ED visits for opioid-related presentations more
than doubling between 2010 and 2018.18,19 Patients who
survive an opioid overdose are 100 times more likely to die
Volume 78, no. 3 : September 2021
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by drug overdose in the following year and 18 times more
likely to die by suicide compared to the general
population.20 One-year mortality following an ED visit for
opioid overdose is 4.7% to 5.5%.12,21,22 Despite the
extraordinarily high mortality, only one third of patients
seen in the ED for nonfatal overdose received medication
for opioid use disorder in the following year.12 Importantly,
compared to patients who did not receive medication for
opioid use disorder after overdose, those who received
buprenorphine had a signiﬁcant reduction in mortality
(adjusted hazard ratio 0.63; conﬁdence interval [CI] 0.46
to 0.87), as did those receiving methadone (adjusted hazard
ratio 0.47; CI 0.32 to 0.71).12 Analysis of another cohort of
6,451 commercially insured patients discharged from an
ED after nonfatal opioid overdose found that only 16.6%
of patients received treatment for opioid use disorder in the
90 following days.23
Emergency physicians have an opportunity to provide
evidence-based interventions and improve the care of
patients with untreated opioid use disorder. Evidence
strongly supports the initiation of pharmacotherapy for
patients with untreated opioid use disorder at any and all
points of contact with the health care system; this has been
advocated by the Surgeon General, the National Institute
on Drug Abuse, the Substance Abuse and Mental Health
Services Administration (SAMHSA), the National
Academy of Sciences, and the American College of
Emergency Physicians (ACEP).24-29 The ED is often the
only contact individuals with opioid use disorder have with
the health care system, and initiating treatment during the
visit can make an enormous contribution to improving
access to lifesaving care for people with opioid use disorder.
Fundamentals: Opioid Use Disorder and Food and
Drug Administration (FDA)-Approved Medications
Opioid use disorder is a chronic disease characterized by
changes in brain function whose pathophysiology, like that of
most chronic diseases, is heavily inﬂuenced by genetic and
environmental factors.30 The Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition criteria for
diagnosing opioid use disorder relate to loss of control,
physiologic changes, and personal consequences, and the
presence of these criteria deﬁnes mild (2 to 3 criteria),
moderate (4 to 5), or severe (6 or more) disease.31 As with
many chronic diseases, pharmacotherapy plays a central, not
adjunctive, role in treatment of opioid use disorder.
Individuals with moderate to severe opioid use disorder are
eligible for initiation of medication for opioid use disorder.
There are 3 medications approved by the FDA for the
treatment of OUD. In the ED, initiation of treatment is
Volume 78, no. 3 : September 2021
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driven by a combination of federal regulation, patient
characteristics, and pharmacological properties. Naltrexone
is a long-acting, competitive m-opioid receptor antagonist
that is used in the treatment of both opioid use disorder
and alcohol use disorder.32 Naltrexone results in
precipitated opioid withdrawal in patients dependent on
opioid agonists, and patients must be abstinent from
opioids for at least 7 to 10 days prior to administration by
any route.26 Naltrexone does not treat opioid withdrawal
and is not as effective at reducing mortality for patients
with opioid use disorder as agonist opioid treatment.12
Methadone is a synthetic m-opioid receptor full agonist
used for treatment of chronic pain and for opioid use
disorder. Although therapeutic use of methadone is
generally safe, rapid dose escalation results in potentially
fatal respiratory depression. Additionally, high doses may
cause a similar effect, which is enhanced by combination
with sedatives.32 Methadone is effective for the
management of opioid withdrawal, and, as a full agonist, it
does not cause precipitated withdrawal. Physicians can
administer methadone in the ED or hospital for the
treatment of opioid withdrawal, but the use of methadone
for the treatment of opioid use disorder is limited to
patients enrolled in regulated opioid treatment programs.33
Buprenorphine, a synthetic partial m-opioid receptor
agonist, is primarily used for the treatment of opioid use
disorder, though it is also prescribed for pain. The m-opioid
receptor afﬁnity is sufﬁciently strong to prevent other
opioids from binding, exerting a “blocking effect.” As a
partial agonist, buprenorphine has a ceiling effect on
respiratory depression, meaning sedation and respiratory
depression is diminished, and it has a similar plateau in
analgesic efﬁcacy.32 Due to its high afﬁnity and partial
agonism at the m-opioid receptor, buprenorphine can
behave as an antagonist by displacing a full agonist bound
to the opioid receptor, leading to precipitated opioid
withdrawal in opioid-dependent patients. In patients with
abstinence-related withdrawal or withdrawal precipitated
by naloxone, buprenorphine provides a sufﬁcient agonist
effect to ameliorate the withdrawal syndrome.
CONSENSUS RECOMMENDATION SCOPE
These recommendations provide evidence-based
assistance for emergency physicians treating ED patients
with opioid withdrawal and initiating treatment for opioid
use disorder with direct linkage to ongoing addiction care.
METHODS
ACEP staff solicited applications from experts in the
ACEP Pain Management and Addiction Medicine Section
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to develop a consensus guideline that was conceived by
ACEP and supported through a grant from SAMHSA.
ACEP staff reviewed and approved applications and
credentials for the 10 responding physicians with expertise
in emergency and addiction medicine, medical toxicology,
administration, and research from diverse practice settings.
Consistent with the patient/population, intervention,
comparisons, and outcomes (PICO) framework, experts
identiﬁed a research question focused on ED practices to
improve outcomes of patients with opioid use disorder to
guide the literature search and consensus
recommendations.34 Recommendations were discussed and
reviewed iteratively by all members throughout the process.
All members attested to meeting International Committee
of Medical Journal Editors guidelines. These consensus
recommendations were reviewed and approved by the
ACEP board of directors on January 28, 2021.
Literature Review
A rapid review was conducted to inform the
development of an evidence-based consensus guideline.
The authors worked with a medical librarian to identify key
words and phrases as well as inclusion and exclusion criteria
to be applied in database searches. The librarian then
performed searches in the MEDLINE and Scopus
databases on July 27, 2020, and August 14, 2020, using
the following key words/phrases or variations and
combinations of the key words/phrases: addiction
treatment, analgesics, opioid, buprenorphine, naloxone
drug combination, buprenorphine/naloxone, clonidine,
harm reduction, heroin, lofexidine, medication for opioid
use disorder, medication-assisted treatment, methadone,
naloxone, opiate substitution treatment, opioid addiction,
opioid overdose, opioid use disorder, opioid withdrawal,
opioid-related disorders, precipitated withdrawal,
suboxone, survival analysis, and thiorphan. All searches
were limited to studies of adult humans. Additional
publications were identiﬁed by reviewing the reference lists
of selected publications and by consulting with content
experts and were used to tailor the literature search.
Resulting titles and abstracts were audited
independently by 2 reviewers (JH and MW) to determine
if the article addressed the PICO elements of treating
withdrawal or initiation of treatment for opioid use
disorder in ED patients with opioid use disorder or opioid
withdrawal with a focus on the outcomes: mortality,
morbidity (including accepting treatment for medical care
not related to opioid use disorder), and linkage to opioid
use disorder treatment. Exclusion criteria included
initiation of opioid use disorder treatment in the
436 Annals of Emergency Medicine
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outpatient setting, even if follow-up measurements
included ED visits; economic impact, even if this involved
the ED; and take-home naloxone, if this was the only
intervention reported.
Data collection and processing. Multiple reports of
single trials were deduplicated by the medical librarian and
subsequently exported to Rayyan.35 The 2 primary
reviewers (JH and MW) initially reviewed titles and
abstracts independently, with subsequent inclusion of
articles by consensus. In case of disagreement, the full text
of the manuscript was examined. Disagreements in which
consensus could still not be reached were resolved with a
third reviewer (KH). All included manuscripts were
subsequently made available to all experts on the consensus
panel, who performed their own individual assessments of
quality and bias.
Rapid literature review results. Seven hundred
seventy-six articles published between January 1, 1970, and
August 14, 2020, were identiﬁed in the searches. After the
inclusion and exclusion criteria were applied, 60 articles
were made available to consensus experts (Table E1,
available at http://www.annemergmed.com).
RESULTS AND RECOMMENDATIONS
Based on the literature review, clinical experience, and
expert consensus, we recommend that ED clinicians treat
opioid withdrawal and offer buprenorphine with direct
linkage to ongoing medication for opioid use disorder
treatment for patients with untreated opioid use disorder.
There is strong evidence demonstrating reduced
morbidity and mortality for patients with opioid use
disorder who are treated with opioid agonist treatment
outside of the ED setting.7-12 Initiating buprenorphine in
the ED is effective for engaging patients in formal addiction
treatment. In a randomized controlled trial, 78% (89 of
114; 95% CI 70% to 85%) of ED patients with opioid use
disorder who received buprenorphine in the ED with
referral for ongoing buprenorphine were engaged in formal
addiction treatment at 30 days, compared to the 37% (38
of 102; 95% CI 28% to 47%) and 45% (50 of 111; 95%
CI 36% to 54%) of patients who received brief
intervention with standard or facilitated referral,
respectively.36 The buprenorphine group reduced the
number of days of illicit opioid use per week from 5.4 days
(95% CI 5.1 to 5.7) to 0.9 days (95% CI 0.5 to 1.3),
versus reductions from 5.4 days (95% CI 5.1 to 5.7) to 2.3
days (95% CI 1.7 to 3.0) in the referral group and from 5.6
days (95% CI 5.3 to 5.9) to 2.4 days (95% CI 1.8 to 3.0)
in the brief intervention group.36 An analysis from the
health care perspective using cost-effectiveness acceptability
Volume 78, no. 3 : September 2021
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curves found that at all positive willingness-to-pay values,
ED-initiated buprenorphine treatment was more costeffective than brief intervention with standard or facilitated
referral.37 Many EDs have instituted buprenorphine
programs, which, alongside the broad state-wide
implementation by the California Bridge Project,38 have
provided evidence of feasibility in ED populations.39-41
Massachusetts adopted legislation (Chapter 208 of the Acts
of 2018) requiring acute care hospitals that provide
emergency services to have protocols and the capacity to
initiate opioid agonist therapy to patients who present after
opioid-related overdoses.42,43 The use of buprenorphine
has increased from 12.3 per 100,000 ED visits in 2002 to
2003 to 42.8 per 100,000 ED visits in 2016 to 2017 (odds
ratio for linear trend 3.31; 95% CI 1.04 to 10.5).44
Patient Selection
Individuals can be identiﬁed during their visit by direct
history taking, review of electronic health record, physical
examination, or screening techniques. In light of the widely
recognized treatment gap and the high mortality of patients
with untreated opioid use disorder, all patients meeting
criteria for opioid use disorder who are not currently
enrolled in treatment should be offered treatment and
assessed for active suicidal ideation.13,18,20
Although concomitant use of buprenorphine and
sedatives increases the risk of adverse outcomes, including
overdose and death, medication for opioid use disorder
should not be denied to patients with this high-risk use. In
2017, an FDA advisory speciﬁcally addressed this issue,
stating that “buprenorphine should not be withheld from
patients taking benzodiazepines or other medications that
depress the central nervous system (CNS), despite potential
side effects, given the potential harm of untreated opioid
use disorder.”45 When initiating buprenorphine, patients
should be educated about the risks of concomitant use
of benzodiazepines, sedatives, opioid analgesics, and
alcohol.
Enhancing Patient Motivation to Start Treatment
Using nonstigmatizing language and normalizing the
process of ED initiation of buprenorphine and referral to
ongoing treatment increases the likelihood that an
individual will accept treatment. The Brief Negotiation
Interview,46 which includes asking permission to discuss
their drug use, providing feedback, and enhancing
motivation by eliciting patients’ reasons to change and
negotiating next steps, is effective. Integration into the ﬂow
of the ED and the electronic record with decisional support
will improve success.47,48
Volume 78, no. 3 : September 2021
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Protocols
Although speciﬁc protocols may vary among EDs, most
include assessment for (1) moderate to severe opioid use
disorder using questions derived from the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition
criteria; (2) the degree of opioid withdrawal by the Clinical
Opiate Withdrawal Scale; and (3) pregnancy. Depending
on the degree of withdrawal, the patient should be offered
treatment with buprenorphine in the ED or provided a
prescription for unobserved (home) induction.49,50 Patients
should be discharged with a prescription for sufﬁcient
buprenorphine until an outpatient appointment to an
opioid treatment provider or program (ideally within 1
week).51,52 If no Drug Addiction Treatment Act of 2000
(DATA 2000)-waivered provider is available, a plan for
access to medication under the “3-day rule” should be
made (further information can be found in the section on
ED Administration of Buprenorphine). The inclusion of
harm reduction strategies (including overdose education
and naloxone distribution) or prescriptions is also an
essential component of the ED visit.53 Sample protocols are
available online, in EM textbooks, and on the ACEP
Emergency Medicine Quality Network Opioid Initiative
website.38,49,50,54-56 In contrast to traditional outpatient
induction protocols and FDA labeling,26 ED-based
protocols often start with administration of at least 8 mg of
buprenorphine for patients with clinical signs of opioid
withdrawal, and some protocols include an option for 24
mg or more during the ED visit based on provider
experience, buprenorphine and/or specialist consultation,
or other factors.38,49,50,54-56
Referrals
Each patient with ED-initiated buprenorphine
should be provided with a direct speciﬁc referral (when
possible, with an appointment time) to a provider that
aligns with the patient’s insurance and other
preferences. EDs should engage their community
stakeholders in protocol development and enhance
bidirectional communication to improve the continuity
of care of patients with opioid use disorder. As with all
chronic diseases, EDs are dependent on local resources.
When no connection to local treatment providers
exists, champions should consider online treatment
provider resources such as the SAMHSA treatment
ﬁnder website,57 which includes information about
treatment services offered and payment/insurance. The
addition of health advocates or navigators in the ED
who assist with motivating patients to accept treatment
and navigating their paths to treatment may facilitate
Annals of Emergency Medicine 437
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better outcomes.39,58 Whether these individuals are
social workers, counselors, or peers, success depends on
their ability to be integrated into the fabric of the
ED.59 A process of reviewing the ﬁdelity of these
interventions to ensure that they are evidence based
should be in place.
Documentation
When prescribing buprenorphine for opioid use
disorder, the diagnosis of opioid use disorder should be
included on the patient’s medical record. Adding the
diagnosis of opioid use disorder in the ED can expedite the
referral process for many outpatient treatment providers
and further support insurance preauthorization requests.
This diagnosis should be supported by ED
documentation.31,60
Implementation Tips
Sustained success is built on the inclusion of
multidisciplinary champions in developing protocols,
normalizing the care of individuals with addiction, and
developing monitoring and feedback systems to the staff.
The inherent nature of ED care means that staff often only
observe the negative consequences of untreated addiction
rather than the successes that patients can have with
evidence-based treatment. Leadership involvement in
setting expectations for initiating treatment of opioid use
disorder and providing referral for long-term addiction care
is critical for departmental practice change.47,61,62
Integrating decision support into the electronic health
record is highly effective for streamlining the process of
ED-initiated buprenorphine with referral for ongoing
treatment and is integral for patient and provider
satisfaction. A pilot test of a user-centered clinical decision
support integrated within the electronic health record more
than doubled prescription rates of ED-initiated
buprenorphine and naloxone while doubling the number of
unique physicians adopting the practice.48,63
DATA 2000 Training/DEA X-waiver
DATA 2000 permitted US physicians to obtain a Drug
Enforcement Administration (DEA) DATA waiver (by
applying to SAMHSA after completing an approved 8-hour
course) to treat patients with opioid use disorder using
buprenorphine, the only schedule III, IV, or V medication
that is FDA-approved for the treatment of opioid use
disorder.64,65 Once SAMHSA approves the physician’s
application, the physician receives an X-waiver designation
from the DEA.
438 Annals of Emergency Medicine
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In all, DATA 2000 enables physicians to prescribe
buprenorphine for opioid use disorder to be ﬁlled by
patients at a pharmacy rather than obtaining medication
from a traditional opioid treatment program. The
Comprehensive Addiction Recovery Act of 2016 allowed
for qualifying physician assistants and nurse practitioners
to obtain X-waivers after completing 24 hours of approved
coursework.66 Patient limits have been incorporated into
both laws, but they refer only to outpatients in
longitudinal care and are unlikely to be a limitation to
emergency clinicians prescribing only from the ED.
Legislative and regulatory efforts are underway to reduce
or eliminate the expectation for training and certiﬁcation
prior to prescribing buprenorphine for patients with
opioid use disorder.67,68 On April 28, 2021, the
Department of Health and Human Services released new
practice guidelines exempting state licensed, DEAregistered clinicians treating up to 30 patients at one time
from completing the 8 (or 24) hour DATA 2000 training
previoulsy required to obtain an X-waiver.69 As patients
count towards a clinicians 30 patient limit until care is
transfered to another clinican or 30 days from prescription
end, most EM clinicians can practice under this
exemption unless prescribing outside of traditional EM
setting. Importantly, physicians must still apply for a Xwaiver by ﬁling a Notice of Intent with SAMHSA, who
may take up to 45 days to approve the application.69
ED Administration of Buprenorphine
An emergency physician has historically been able to
administer buprenorphine in the ED under the “3-day
rule” without having obtained an X-waiver.70 A patient
may be discharged and return to the ED repeatedly within
72 hours to receive medication from the same or a different
provider. The dose is not speciﬁed; however, the
medication must be administered to the patient while in
the ED. The “3-day rule” was recently modiﬁed in the
Further Continuing Appropriations Act, 2021, and Other
Extensions Act, which was signed into law on December
11, 2020.71 The Act requires the Attorney General (who
will delegate this responsibility to the DEA), within 180
days, to revise current regulations governing the 3-day rule
to allow practitioners to dispense not more than a 3-day
supply of medication to one person or for one person’s use
at one time for the purpose of initiating maintenance
treatment or detoxiﬁcation treatment (or both) without a
DATA 2000 waiver.
Patients with opioid use disorder who are being
admitted to the hospital for a medical condition may be
initiated and maintained on medication for opioid use
Volume 78, no. 3 : September 2021
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disorder treatment while hospitalized without restriction,
even without a DATA waiver.
Special Populations
Historically, buprenorphine as a single agent (without
naloxone) was considered the preferred formulation for
pregnant patients requiring medication for opioid use
disorder, although recent investigation has revealed no
adverse events with the combined buprenorphine/naloxone
product.72 The American College of Obstetrics and
Gynecology recommends the use of either formulation.73
The addition of naloxone to buprenorphine is intended to
reduce intravenous use, misuse, diversion, and street value,
though it does have a higher cost to the uninsured patient.
Buprenorphine is approved for patients aged 16 years and
older and should be considered for adolescents with opioid
use disorder.33 It is important to check local regulations
and hospital policy before prescribing to adolescents.
Buprenorphine can be safely used in geriatric patients with
opioid use disorder; however, as it is an opioid, dosing may
need to be adjusted and education should be provided to
the patient and family regarding the risk of concomitant
use of sedating medications.
Stigma and Language
Patients report feeling heavily stigmatized during health
care interactions, sometimes leading to distrust and an
unwillingness to seek medical care.74-76 Best practices
support the avoidance of stigmatizing and derogatory terms
such as “abuse,” “addict,” and being “clean.”74,75 Language
should be patient-centered, professional, and objective. For
example, person-centered language such as “person who
injects drugs” and “patient with an opioid use disorder”
avoid negative connotations and conﬂation of the
individual with speciﬁc behaviors to facilitate the
development of a therapeutic alliance with the patient.
Given the evidence supporting a central role of
pharmacotherapy in the treatment of opioid use disorder,
many professionals are making a concerted effort to move
away from the term “medication-assisted treatment,
replacing it with more accurate terminology, “medication
for opioid use disorder.”26,74,27 Those who desire to
preserve the medication-assisted treatment acronym often
use “medication for addiction treatment.”77 The updated
terminology conveys that medication, or the option of it, is
essential for treating patients with opioid use disorder,
while the term “medication-assisted treatment” implies that
medication is more of an adjunctive therapy.77-79 Stigma is
often unwitting, unrecognized, and unaddressed by
physicians, and stigmatizing attitudes, language, and
Volume 78, no. 3 : September 2021

Treatment of Opioid Use Disorder in the Emergency Department

behaviors are often solidiﬁed during training. Raising
awareness of nonpatient-centered language, attitudes, and
behaviors among all members of the health care team is
essential to transforming ED culture and care of opioid use
disorder.
CONCLUSION
Detecting and offering evidenced-based treatments for
patients with opioid use disorder is aligned with the goals of
emergency medicine to intervene on high-mortality disease
processes. The window of opportunity to begin lifesaving
pharmacotherapy may be ﬂeeting. The ED’s 24-hour, 365day accessibility ideally positions it as a cornerstone of care
to close the enormous treatment gap for patients with
opioid use disorder.61
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